Next Generation Sequencing Screening for Embryonic Ploidy Status
Completed · Not applicable
Conditions studied: Infertility
In brief
To evaluate the benefits of using next generation sequencing to assess embryonic aneuploidy. All viable blastocysts will be biopsied and cryopreserved for future transfer. After the final embryo is cryopreserved, patients will be randomized to either the intervention group or the control group. Patients and doctors are blinded to the randomization until study completion. A Double Embryo Transfer (DET) will be performed with either screened or unscreened embryos depending on randomization. A Single Embryo Transfer (SET) may occur in cases where only one embryo is available for transfer.
Key facts
- Study ID
- NCT02032264
- Run by
- Reproductive Medicine Associates of New Jersey
- People needed
- 309
- Starts
- 2013-12-01
- Expected to finish
- 2017-01-01
- Last updated by the study team
- 2017-03-17
Who can join
Age: 18 and older, up to 42. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Patient undergoing IVF/CCS (no PGD banking)
- Patient meets ASRM guidelines for Double Embryo Transfer (DET)
- Donor Sperm OK
- AMH ≥ 1.2
- FSH ≤ 12
- BAFC ≥12
- Max 1 prior failed IVF cycle for patients 35-45 years old
- Patient <35 years old MUST have 1 prior failed IVF cycle
You may not qualify if…
- Chronic endometrial insufficiency
- Use of oocyte donor or gestational carriers
- Medical contraindications to Double Embryo Transfer (DET)
- Male Factor (<100,000 sperm or surgical sperm)
- Communicating hydrosalpinx (on HSG)
- Single gene disorders or sex selection
Where it is running
- Reproductive Medicine Associates of New Jersey — Basking Ridge, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.